Filtered By:
Condition: Heart Failure
Drug: Beta-Blockers

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 190 results found since Jan 2013.

Impact of Atrial Fibrillation on Exercise Capacity in Heart Failure With Preserved Ejection Fraction: A RELAX Trial Ancillary Study Original Articles
Conclusions— AF identifies an HFpEF cohort with more advanced disease and significantly reduced exercise capacity. These data suggest that evaluation of the impact of different rate or rhythm control strategies on exercise tolerance in patients with HFpEF and AF is warranted. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00763867.
Source: Circulation: Heart Failure - January 21, 2014 Category: Cardiology Authors: Zakeri, R., Borlaug, B. A., McNulty, S. E., Mohammed, S. F., Lewis, G. D., Semigran, M. J., Deswal, A., LeWinter, M., Hernandez, A. F., Braunwald, E., Redfield, M. M. Tags: Congestive, Exercise/exercise testing/rehabilitation, Arrhythmias, clinical electrophysiology, drugs Original Articles Source Type: research

A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry
Conclusion The EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot Registry has provided systematic collection of contemporary data regarding the management and treatment of AF by cardiologists in ESC member countries. Oral anticoagulant use has increased, but novel OAC use was still low. Compliance with the treatment guidelines for patients with the lowest and higher stroke risk scores remains suboptimal.
Source: Europace - February 25, 2014 Category: Cardiology Authors: Lip, G. Y. H., Laroche, C., Dan, G.-A., Santini, M., Kalarus, Z., Rasmussen, L. H., Oliveira, M. M., Mairesse, G., Crijns, H. J. G. M., Simantirakis, E., Atar, D., Kirchhof, P., Vardas, P., Tavazzi, L., Maggioni, A. P. Tags: Atrial fibrillation Source Type: research

Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial
Conclusions Among maintenance dialysis patients with hypertension and left ventricular hypertrophy, atenolol-based antihypertensive therapy may be superior to lisinopril-based therapy in preventing cardiovascular morbidity and all-cause hospitalizations. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases; ClinicalTrials.gov number: NCT00582114)
Source: Nephrology Dialysis Transplantation - February 28, 2014 Category: Urology & Nephrology Authors: Agarwal, R., Sinha, A. D., Pappas, M. K., Abraham, T. N., Tegegne, G. G. Tags: Intra- and Extracorporeal Treatments of Kidney Failure Source Type: research

Orthostatic hypotension is associated with more severe hypertension in elderly autonomous diabetic patients from the French Gerodiab study at inclusion.
CONCLUSION: About one-third of elderly, autonomous diabetic patients had OH. They had more severe hypertension, with higher SBP, DBP and PP at rest. However, the number of anti-hypertensive drugs did not differ compared to patients without OH. This could reflect the medical teams' fears about intensifying treatment. PMID: 24958527 [PubMed - as supplied by publisher]
Source: Annales de Cardiologie et d'Angeiologie - June 7, 2014 Category: Cardiology Authors: Bouhanick B, Meliani S, Doucet J, Bauduceau B, Verny C, Chamontin B, Le Floch JP, Gerodiab Study Group Tags: Ann Cardiol Angeiol (Paris) Source Type: research

Beta-blockers in Pediatric Hypertrophic Cardiomyopathies.
Conclusions: Beta-blocker therapy is without doubt the treatment of choice for patients with heart failure caused by hypertrophic cardiomyopathy, but the dose needs to carefully titrated on an individual basis for maximum benefit, and the dose required is surprisingly large in infants with heart failure due to hypertrophic cardiomyopathy. PMID: 25198737 [PubMed - as supplied by publisher]
Source: Reviews on Recent Clinical Trials - September 8, 2014 Category: Cancer & Oncology Authors: Ostman-Smith I Tags: Rev Recent Clin Trials Source Type: research

Particularities in coronary revascularization in elderly patients presenting with ST segment elevation acute myocardial infarction (STEMI)
Publication date: August 2014 Source:Cor et Vasa, Volume 56, Issue 4 Author(s): Maria Dorobanţu , Lucian Câlmâc , Andrada Bogdan , Vlad Bătăilă , Bogdan Drăgoescu , Andrei Radu , Mugur Marinescu , Şerban Arvanitopol , Gabriel Tatu-Chiţoiu , Rodica Niculescu Nowadays, ST elevation acute myocardial infarction (STEMI) is seen with greater incidence in older patients. Current guidelines recommend an immediate invasive evaluation and eventually primary percutaneous coronary intervention (PCI) in all STEMI patients regardless of age. Nevertheless, data in literature show a significant underuse of interventional treatm...
Source: Cor et Vasa - November 1, 2014 Category: Cardiology Source Type: research

Ronald Reagan UCLA Medical Center recognized with award for heart failure care
Ronald Reagan UCLA Medical Center has received the American Heart Association’s Get With The Guidelines – Heart Failure Gold-Plus Quality Achievement Award. The award recognizes the hospital’s work implementing quality improvement measures outlined by the American Heart Association/American College of Cardiology Foundation guidelines for heart failure patients. This marks the sixth consecutive year that Ronald Reagan UCLA Medical Center has been recognized with a quality achievement award for its work treating heart failure. Get With The Guidelines – Heart Failure is a quality improvement program that helps hospita...
Source: UCLA Newsroom: Health Sciences - November 14, 2014 Category: Universities & Medical Training Source Type: news

Beta-blocker Use for Toxicity From “Bath Salts”
We appreciate the review of synthetic cathinones (“bath salts”) by Dr. Banks and colleagues (1). The long half-lives of these drugs are similar to methamphetamine, and persistent tachycardia and hypertension are problems that may lead to secondary injury such as acute coronary syndrome, heart failure, arterial dissection, and stroke (2–6). Indeed, the authors recognize this and write, “What is evident in these case reports is that tachycardia is more severe and more prevalent than hypertension; heart rates are commonly reported> 150 beats/min, whereas concomitant blood pressure (BP) might be normal or only mildly (systolic BP 
Source: The Journal of Emergency Medicine - November 18, 2014 Category: Emergency Medicine Authors: John R. Richards, Erik G. Laurin, Timothy E. Albertson Tags: Letter to the Editor Source Type: research

Myocardial infarction in older than 75 years: An increasing population. CASTUO study
Conclusions Patients older than 75 years with acute myocardial infarction had lower survival and were treated with fewer beta-blockers, statins and angioplasty, indications that are associated with lower mortality.
Source: Revista Clinica Espanola - January 16, 2015 Category: Internal Medicine Source Type: research

Predictors of long-term outcomes in hypertrophic cardiomyopathy patients undergoing cardiopulmonary stress testing and echocardiography
Conclusions In HCM patients undergoing CPT, a higher % of achieved age-gender predicted V02 and surgical relief of LVOT obstruction were associated with better outcomes, while abnormal HRR, atrial fibrillation and lower LVEF were associated with worse outcomes.
Source: American Heart Journal - February 25, 2015 Category: Cardiology Source Type: research

Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial
This study is registered at clinicaltrials.gov-NCT00417222.
Source: European Heart Journal - April 14, 2015 Category: Cardiology Authors: Sakata, Y., Shiba, N., Takahashi, J., Miyata, S., Nochioka, K., Miura, M., Takada, T., Saga, C., Shinozaki, T., Sugi, M., Nakagawa, M., Sekiguchi, N., Komaru, T., Kato, A., Fukuchi, M., Nozaki, E., Hiramoto, T., Inoue, K., Goto, T., Ohe, M., Tamaki, K., I Tags: Heart failure/cardiomyopathy Source Type: research

Abstract 118: Discharge Medications, Hospice Use and 30 Day Outcomes for Hospitalized Heart Failure Patients Session Title: Poster Session I
Conclusions: As heart failure progresses, transfer to palliative or hospice services is often appropriate. Including patients when death is imminent in outcome analyses could overestimate medication effects. Mechanisms for identifying such patients other than hospice use are limited but constitute an important goal for future research.
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Stearns, S. C., Rodgers, J. E., Chang, P. P., Sueta, C. A. Tags: Session Title: Poster Session I Source Type: research

{beta}-blockers in pulmonary arterial hypertension: evolving concepts of right heart failure
Current guidelines advise against the use of β-blockers in pulmonary arterial hypertension (PAH) to avoid systemic hypotension [1]. In addition, PAH patients have a fixed stroke volume, and are therefore highly dependent on heart rate to increase their cardiac output [2–4]. Indeed, Provencher et al. [5] showed that withdrawal of β-blockers significantly improved exercise capacity in portopulmonary hypertension. Peacock and Ross [6] described another case of portopulmonary hypertension, in which the use of a β-blocker to treat a supraventricular tachycardia in an already haemodynamically unstable patient was nearly fatal.
Source: European Respiratory Journal - August 31, 2015 Category: Respiratory Medicine Authors: de Man, F. S., Handoko, M. L. Tags: Pulmonary vascular disease Editorials Source Type: research

Prognostic and symptomatic benefits with ivabradine: lessons from the SHIFT trial
Ivabradine, a funny current (If) inhibitor, has been developed for symptomatic therapy of angina and in chronic heart failure (CHF) with low ejection fraction. A large outcome trial, SHIFT (Systolic Heart Failure Treatment with the If inhibitor ivabradine trial), was conducted in patients with EF ≤ 35% in sinus rhythm and increased heart rate ≥70 b.p.m. It demonstrated that the addition of this new compound to the best possible contemporary therapy, including beta-blockers, was associated with a 18% relative risk reduction in the occurrence of cardiovascular mortality or hospitalization for worsening heart failure (H...
Source: European Journal of Heart Failure Supplements - December 16, 2015 Category: Cardiology Authors: Komajda, M. Tags: Articles Source Type: research

Clinical characteristics, management and 1-year outcomes of patients with acute coronary syndrome in Iran: the Iranian Project for Assessment of Coronary Events 2 (IPACE2)
Conclusions Our study showed that the composition of Iranian patients with ACS regarding the type of ACS is similar to that in developed European countries and is unlike that in developing countries of the Middle East and Africa. We found that our patients with ACS are treated with high levels of adherence to guideline-recommended in-hospital medications.
Source: BMJ Open - December 15, 2015 Category: Journals (General) Authors: Kassaian, S. E., Masoudkabir, F., Sezavar, H., Mohammadi, M., Pourmoghaddas, A., Kojouri, J., Ghaffari, S., Sanaati, H., Alaeddini, F., Pourmirza, B., Mir, E., on-behalf of the IPACE2 registry investigators Tags: Open access, Cardiovascular medicine, Evidence based practice, Medical management Research Source Type: research